Compare LYFT Inc (LYFT) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LYFT Inc vs Twist Bioscience Corp — how do they compare? LYFT Inc trades at $16.24 (market cap $6.11B), while Twist Bioscience Corp trades at $163.14 (market cap $10.08B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, LYFT Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold LYFT Inc for 47 Days and Twist Bioscience Corp for 27 Days on average.
| LYFT | TWST | |
|---|---|---|
Market Cap | $6.11B | $10.08B |
Volume | 13,504,560 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $24.57 | $205.00 |
52-Week Low | $12.65 | $25.45 |
Typical Hold Time | 47 Days | 27 Days |
Enterprise Value | $5.57B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lyft (LYFT) trades at $16.27, up 4.29% with bullish technical signals from moving averages and ADX indicators. The company shows remarkable financial improvement with 2025 revenue of $6.32B and net income of $2.84B, achieving a 45.02% profit margin. Recent developments include European expansion and a $272.5M legal settlement. Valuation metrics appear attractive with P/E of 2.35 and P/S of 0.96, though EV/EBITDA remains elevated at 34.55.
Lyft presents a mixed investment case with strong profitability growth offset by competitive pressures and regulatory risks. The stock trades below analyst consensus target of $18.07, offering potential upside, but faces challenges from driver classification lawsuits and market saturation concerns. Recent earnings misses and high RSI levels suggest near-term volatility despite positive cash flow trends and institutional support.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
